Immunogenicity and protection of oral influenza vaccines formulated into microparticles
نویسندگان
چکیده
منابع مشابه
Prophylactic Vaccines Based on CureVac’s RNActive® Technology Demonstrate Immunogenicity and Protection Against Influenza Virus Infection
TUEBINGEN, Germany, Nov. 25 – CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company’s RNA technology platform have the potential to provide effective protect...
متن کاملEvaluation and Comparison of the Potential Immunogenicity of Two Commercial Inactivated Bivalent Newcastle and Avian Influenza Vaccines in SPF Chicken
In the present study, the potency and immunogenicity of the inactivated bivalent vaccine of Newcastle disease (ND) and avian influenza (AI) produced by Razi institute in Iran were compared with a similar imported vaccine administered by standard methods to specific-pathogen-free (SPF) chicken. A total of 150 twenty-one-day-old SPF chickens were used for evaluating Razi and imported inactivated ...
متن کاملImmunogenicity and Efficacy of Different Haemophilus influenzae type b Vaccines
Haemophilus influenzae, a major cause of meningitis in young children leading to death and other neurological sequelae. The disease leaves 15 to 35% of the survivors with permanent disabilities, such as, mental retardation or deafness. Despite the availability of new and more powerful antibiotics children with Hib meningitis still suffer from high mortality or morbidity. The emergence of multir...
متن کاملImmunogenicity of Concentrated and Purified Inactivated Avian Influenza Vaccine Formulation
Avian influenza (AI) H9N2 is a low pathogenic virus subtype belonging to Orthomyxoviridae family. Given the prevalence of this subtype as an infectious agent in poultry industry, special attention has been always directed toward the development of vaccine production against this infection. The vaccine of this infection is produced by killing the virus and using a mixture of inactivated antigen ...
متن کاملMechanisms of Cross-protection by Influenza Virus M2-based Vaccines
Current influenza virus vaccines are based on strain-specific surface glycoprotein hemagglutinin (HA) antigens and effective only when the predicted vaccine strains and circulating viruses are well-matched. The current strategy of influenza vaccination does not prevent the pandemic outbreaks and protection efficacy is reduced or ineffective if mutant strains emerge. It is of high priority to de...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Pharmaceutical Sciences
سال: 2012
ISSN: 0022-3549
DOI: 10.1002/jps.23220